Dishman Pharmaceuticals posted a 13.24% topline growth in the fourth quarter of FY12 and reported a consolidated net profit of Rs 312.94 million for the quarter ended 31 March, 2012, up 37.30% from Rs 227.92 million in the corresponding quarter last year.
first published: May 15, 2012 04:33 pm
A collection of the most-viewed Moneycontrol videos.
Relief Rally in Global Markets 🌍 | Oil Cools, Hormuz Tensions | Nifty 23,500 in Focus | Opening Bell
Iran-US War Update: “No War” Starmer Rejects Iran Conflict, Announces £53M Support Plan
Reliance Foundation Chairperson Nita Ambani Visits KISS to Receive Humanitarian Award
US-Iran War Update: “We Didn’t Start This” Germany Rejects Trump’s Push for Action Against Iran
